在PASMCs中的Piezo1:对缺氧诱导的肺高血压发展至关重要
Fenja Knoepp1, Shariq Abid2,3, Amal Houssaini2,4
1Excellence Cluster Cardio-Pulmonary Institute, Universities of Giessen and Marburg Lung Center, Member of the German Center for Lung Research, Justus Liebig University (F.K., M.Y.G., A.G., S.K., I.B.-M., K.Q., D.F.-N., N.W.).
Circulation research
|April 4, 2025
概括
肺动脉平滑肌细胞中的机械敏感离子通道Piezo1通过增加细胞增殖和血管收缩驱动肺高血压. 阻断Piezo1可以防止PH的发展,并保护肺血管.
科学领域:
- 心血管研究研究心血管研究
- 肺部医学 肺部医学
- 细胞机械生物学 细胞机械生物学
背景情况:
- 肺高血压 (PH) 是一种渐进的,无法治愈的疾病,其特征是肺动脉光滑肌细胞 (PASMC) 收缩和增殖.
- 肺动脉中改变的机械应激是PH期间PASMC功能障碍的关键刺激.
- 机械敏感离子通道,如Piezo1,将机械刺激转化为与PH病原发生相关的细胞反应.
研究的目的:
- 研究Piezo1在PASMCs在PH的发展和进展中的特定作用.
- 确定Piezo1在PASMC中的向是否可以改善PH相关的病理.
主要方法:
- 在PASMC和PH患者的肺组织中评估Piezo1表达.
- 使用了特定于光滑肌肉细胞的条件Piezo1淘汰赛小鼠模型.
- 在隔离的小鼠肺部,肺动脉和慢性缺氧诱导PH后体内评估Piezo1功能.
主要成果:
- 来自PH患者的PASMC显示Piezo1表达和扩散的增加.
- 在PASMC中,Piezo1淘汰阻止了缺氧诱导的增殖,并减少了血管收缩.
- 缺少皮埃佐1的小鼠受到PH的保护,表现出改善的血液动力学和保存的肺毛细血管.
结论:
- 在PASMC中,Piezo1是PH病变发生的关键媒介.
- 准Piezo1影响肺血管度,动脉重塑和内皮细胞衰老.
- Piezo1代表了治疗肺高血压的潜在治疗标.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
123
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
123
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
110
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
110
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
103
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
103


